Section des sciences pharmaceutiques

Nonadherence to Oral Targeted Anticancer Drugs: What's the Problem and How to Address It?

Prof. Marie Schneider, pharmacist, PhD

Pharmacie communautaire, Section des sciences pharmaceutiques, Université de Genève, Université de Lausanne, Suisse

11th Swiss Pharma Day 2018, Bern, August 22nd, 2018







Outline

- 1. Introduction on medication adherence in oncology
- Review of the literature: breast cancer; chronic myeloid leukemia (CML); gastrointestinal stromal tumor (GIST); non-small cell lung cancer
- 3. Patient education programs
- 4. Our on-going research project
- 5. Take-home messages









Introduction

- Patients prefer oral to intravenous chemotherapy (Liu et al. 1997)
- Adherence: process by which patients take their medications as prescribed



- A behaviour which seems easy for the patient...
- A behaviour that seems easy to support for healthcare professionals ...
- A behaviour that seems easy to investigate in research ...
- ... but which is extremely complex
- And healthcare providers and community pharmacists are at the interface








Ecole de Pharmacie

Definition - Medication adherence



Patient does not initiate treament

Binary (yes/no)

Patient delays, omits or takes extra doses

Dosing history

Patient discontinues treatment

Time to event

Different forms of nonadherence

EU-sponsored research

Vrijens et al. Br J Clin Pharmacol. 2012;73:691-705








Medication adherence as a corner stone to drug cost-effectiveness

↓ Hospitalisations



Heart failure

Riegel et al. Patient Preference and Adherence 2014;8:1-13

Therapeutic failures

Chronic myeloid leukemia CCyR

Ibrahim et al. Blood 2011;117(14):3733-6.

↓ Mortality

HIV

Glass et al. AIDS 2015; 29:2195–2200








Cancers are becoming chronically manageable diseases

- Large scale use of oral targeted treatments in cancer
- Inter- and intra-individual variability in drug exposure
- Nonadherence is a public health issue



Von Mehren and Widmer. Cancer Treatment Reviews 37 (2011) 291–299








Fig. Proportion of patients with poor adherence by cancer type (poor adherence defined as < 90% adherent). NOTE. Percentages are out of total number of participants with available Medication Event Monitoring System data (n = 82).


Jacobs et al. Journal of Oncology Practice

2017;13(5):e473-485



Adherence to protein kinase inhibitors (PKI) and outcomes

- Despite large variability in pharmacokinetics, PKI are registered at a fixed oral dose.
- Proven exposure-response relation
- Challenge in research: dose optimization



Mathijssen et al. Nat Rev Clin Oncol 2014;11:272-281 Rowland et al. Expert Opinion on drug metabolism and toxicology 2017;13(1):31-49 Cardoso, Csajka, Schneider, Widmer. Clin Pharmacokinet 2018;57(1):1-6








Impact of patient adherence



Unpredictable profile of adherence: >700 determinants

(Kardas et al. Frontiers Pharmacology 2013)




www.who.org Adherence to long-term therapy. Evidence for action. 2003 (accessed 02.08.2018)

Marin 2010, Barthelemy 2015, Rychter 2017, Jacobs 2017; Breccia 2015, Murphy 2012, Cluze 2012, Myrick 2012, Geynisman 2013





Determinants of adherence to tyrosine kinase inhibitors





Verbrugghe et al.

2016;39(2):153-162

Cancer Nursing





Methods for measuring medication adherence

Table 2. Measures of Adherence.				
Measure	Pros	Cons		
Direct				
Direct observation	Most accurate Not feasible in real-world pr			
Serum drug levels	Objective measure of recent exposure to drug Can be manipulated; acceptable raunknown; assays not widely available.			
Indirect				
Pill counts	Inexpensive Difficult in real-world practice; easy manipulate; may overestimate adheredemeaning			
MEMS (microelectronic event monitoring system)	Accurate data on when one opens the bottle; may be combined with reminder systems	Not easily feasible in real-world practice; expensive		
Refill records	Objective higher level data; good for research purposes	Report fill rate and not actual intake; impractical for daily use		
Biomarkers	May be important intermediaries to outcomes (e.g., hypertension with TKI use)	Few developed and validated		
Outcomes	Most important variable	Difficult to discern nuances of adherence outside of clear extremes		
Indirect and Subjective				
Self-report	Quick; can use past validated instru- ments; does not require clinician time	Subject to significant bias such as the Hawthorne effect and overestimates adherence		
Assessment by others	Inexpensive; allows for a dialogue	Hawthorne effect; time consuming		
Diaries	Inexpensive; actively involves the patient	Subject to manipulation; demeaning; time consuming		

Geynisman Discov Med. 2013;15(83):231-41







Outline

- 1. Introduction on medication adherence in oncology
- 2. Review of the literature: breast cancer; chronic myeloid leukemia (CML); gastrointestinal stromal tumor (GIST); non-small cell lung cancer
- 3. Patient education programs
- 4. Our on-going research project
- 5. Take-home messages











Prevalence of nonadherence and mortality in breast cancer

- Prevalence of nonadherence: 28 to 59%
- 5-year nonpersistence: 31 to 73%

- (Murphy et al. Breast Cancer Res Treat 2012;134:459–478)
- Noninitiation in patients age ≥ 65 yrs: 14% (Sheppard et al. J Clin Oncol 2014;32:2318-2327)
- Low adherence and early nonpersistence are independent predictors of mortality.





Hershman et al. Breast Cancer Res Treat (2011) 126:529–537








Prevalence of non-adherence in Chronic Myeloid Leukemia (CML)

- 26.4% (Ibrahim et al. Blood. 2011; 117(14):3733-3736)
- 32.7% (ADAGIO study, Noens et al. Blood 2009; 113:5401-5411)
- 36.6% (Santoleri et al. Acta Haematol 2016;136:45–51)



90% adherence cutoff (Santoleri et al. Acta Haematol 2016;136:45-51)









Ecole de Pharmacie PG Genève - Lausanne

Probability of 6-year response in Chronic Myeloid Leukemia (CML)



MMR: major molecular response 13.9% if adherence ≤90% (23 pts) vs. 93.7% if adherence >90% (64 pts)



CMR: complete molecular response 43.8% vs 0%

Adherence is an independent predictor of MMR (RR 11.7, p=.001) and CMR.

Marin et al. *J Clin Oncol* 2010:28;2381-2388







Adherence to imatinib (>90%) is associated with lower health care utilization and costs

	Good Adherence (MPR ≥ 90%)	Medium Adherence (MPR, 70%– < 90%)	Poor Adherence (MPR < 70%)	P Value (Good vs. Medium)	P Value (Good vs. Poor)	
Utilization and costs: entire follow-up period, mean (SD)						
CML	N = 122	N = 103	<i>N</i> = 149			
Inpatient hospital stays	0.5 (1.2)	0.9 (2.8)	1.9 (3.5)	0.312	< 0.001	
Inpatient length of stay, days	3.8 (12.3)	8.4 (27.6)	21.0 (43.1)	0.156	< 0.001	
Total medical costs, \$	30,212 (51,602)	61,702 (149,568)	133,072 (236,511)	0.072	< 0.001	
Total health care costs, \$	120,762 (152,346)	131,465 (152,346)	172,050 (240,434)	0.555	0.021	

Halpern et al. JCOM 2009; 16 (5):215-223.








GIST patients:

Imatinib plasma levels are correlated with clinical benefit



Non-persistence to imatinib is associated with rapid progression even in patients who had achieved complete remission.

Von Mehren, Widmer. Cancer Treatment Reviews 2011;37:291–299 Le Cesne et al. J Clin Oncology 2011;29(15 suppl):10015







Erlotinib in non-small cell lung cancer

- Over one third of patients had an adherence <95%
- At 1-month, 21% patients did not always take the treatment under fasting conditions.
- AUCss was higher in patients with adverse effects (p = <0.05)
- 31% (n = 19/62) reported adverse effects as a reason for non-persistence

Timmers et al. J Cancer Res Clin Oncol 2015; 141:1481-1491







Ecole de Pharmacie FOGEN Genève - Lausanne

Adherence to targeted therapies decreases with time

Duration of therapy

Number of patients reporting skipping TKI doses n = 72

Number of patients, not reporting skipping TKI doses n = 68

P value (

OR [95% PU]

Skipping doses within the entire duration of treatment

<1 year

 ≥ 1 -<2 years

≥2 years

4 (5.6%)

8 (11.1%)

60 (83.3%)

22 (32.4%)

14 (20.6%)

32 (47.0%)

< 0.001

3.1 [0.8–12.4]

10.3 [3.3–32.5]

Rychter at al. Med Oncol (2017) 34:104 Santoleri et al. Acta Haematol 2016;136:45–51

Bathelelmy et al. Oncology 2015;88:1-8







Outline

- 1. Introduction on medication adherence in oncology
- Review of the literature: breast cancer; chronic myeloid leukemia (CML); gastrointestinal stromal tumor (GIST); non-small cell lung cancer
- 3. Patient education programs
- 4. Our on-going research project
- 5. Take-home messages









Patient education in cancer care

- Lack of adherence intervention studies for oral anticancer agents (Mathes 2014 Cancer Treatment Reviews)
- Better patient education (Barthélémy Oncology 2015;88:1–8)
- Interprofessional care (Paolella et al. Pharmacy 2018, 6, 23; doi:10.3390)

Patients

Oncologists and Other Healthcare Professionals

Oral Therapies

Receive extensive amounts of information (e.g., administration, side effects) from oncology team in order to independently deliver, monitor, and safely handle oral anticancer medications. Increased communication with outside

providers and practitioners who might not be cancer care specialists Opportunity to educate and counsel patients at their respective health and digital literacy levels with the intention of better self-management

Non-verbal communication of patients unobservable during drug administration with the medication administered at home. Visual ques such as body fatigue, stress, and overall gestalt require patient to initiate conversation.








Patient care in cancer: CML

41% of CML patients reported that would like to discuss about discomfort, anxiety and fear of the future

What issues related to the illness and treatment would you like to talk about but you can't?



Breccia et al. Leukemia Research 2015;39:1055-1059







Patient care in breast cancer

"Improving persistence to adjuvant cancer therapy in premenopausal women is an important challenge for oncologists and other health care workers.

They must take more time to explain the role of therapy, to describe its sideeffects, and to emphasize its importance.

Although the physician is likely to be the first person to explain the treatment, nurses and other health care professionals can deliver repeated information during follow-up."

Cluze et al. Annals of Oncology 2012; 23: 882–890







Interprofessional Medication adherence program IMAP (Lausanne, Switzerland)

Support and reinforce medication adherence and patient's autonomy


Motivational interviewing patient- pharmacist

Medication Event Monitoring System (MEMS®)

Medication adherence report







Lelubre M., Schneider M. et al. BioMed Research International 2015, Article ID 103546. DOI.org/10.1155/2015/103546 Schneider, Herzig, Hugentobler, Bugnon, RMS 2013;9:1032-6





Theoretical model of the IMAP program IMB

Information Motivation Behaviour

Moderators - Psychology health; Living situation; Information Access to care; - Addiction **Behavioural &** Adherence **Outcomes** management skills Motivation DINIVERSITE

Genève - Lausanne

Fisher et al. Health Psychology 2006; 25,4, 462–473





Outline

- 1. Introduction on medication adherence in oncology
- Review of the literature: breast cancer; chronic myeloid leukemia (CML); gastrointestinal stromal tumor (GIST); non-small cell lung cancer
- 3. Patient education programs
- 4. Our on-going research project
- 5. Take-home messages









Ecole de Pharmacie PGENERAL Genève - Lausanne

Optimization of Targeted Anticancer Therapies(OpTAT)



HSR-4077-11-2016 Optimizing targeted anti-cancer therapies: from better medication adherence to individualized treatments

PI and co-PI:

- Prof. Marie Schneider, Medication adherence program, Pharmacy, Outpatient Medical Clinic, PMU, Lausanne
- Prof. Chantal Csajka, Clinical Pharmacology, CHUV, Lausanne
- Dre Dorothea Wagner, Medical Oncology, CHUV, Lausanne

PhD student: Evelina Cardoso







Objectives of the OpTAT study

- 1. Evaluation of the effect of the medication adherence program on patient self-management and treatment effectiveness compared to usual care.
- 2. Determination of the relation between dose-plasma drug concentrations and efficacy / toxicity endpoints to define or confirm thresholds maximizing treatment success and minimizing toxicity.
- 3. Analysis of the relation between adherence and plasma drug concentrations.







Randomized clinical design (OpTAT)

Randomisation



Medication adherence program

- Electronic monitoring
- Monthly motivational interviewing
- Interprofessional collaboration

Standard care

Blinded electronic monitoring

Sample size: 204 patients in 5 years

Study duration: 12 months







Protein kinase inhibitors under investigation (OpTAT)

Indication	PKIs approved by FDA		
Leukemia	lmatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib		
Gastrointestinal stromal tumors (GIST)	lmatinib, Sunitinib, Regorafenib		
Non-small cell lung cancer (NSCLC)	Gefitinib, Erlotinib, Crizotinib, Afatinib		
Pancreatic cancer	Erlotinib, Sunitinib		
Hepato-cellular carcinoma (HCC)	Sorafenib		
Renal cell carcinoma (RCC)	Sorafenib, Sunitinib, Pazopanib, Axitinib		
Thyroid cancer	Sorafenib, Vandetanib, Cabozantinib		
Breast cancer	Lapatinib palbociclib		
Colorectal cancer (CRC)	Regorafenib		
Melanoma	Vemurafenib, Dabrafenib, Trametinib, <i>Cobimetinib</i>		








13.02.2010

Clinical cases



10.04.2010

17.04.2010

03.04.2010

70 years old, GIST, imatinib 400mg 1-0-1

06.03.2010

13.03.2010

20.03.2010

Capecitabine, 2-0-2, 2 weeks q21 days Green: periods ON

Red: periods OFF

Achtari, Schneider, Bugnon, Lüthi. Rev Med Suisse 2011;7:1154-60

27.03.2010



27.02.2010

20.02.2010





09.01.2009

27.12.2008



Take-home messages



Perspective

April 2010

Thinking Outside the Pillbox — Medication Adherence as a Priority for Health Care Reform

David M. Cutler, Ph.D., and Wendy Everett, Sc.D.

N Engl J Med 2010; 362:1553-1555 | April 29, 2010 | DOI: 10.1056/NEJMp1002305

- Medication adherence is a public health priority in cancer
- Medication adherence has to be monitored in cancer clinical trials but also in real-life routine care, in other malignancies than breast cancer, CML or GIST, and with other targeted treatments than imatinib.
- Responsibility has to be shared between patients and healthcare professionals
- Interprofessional role of pharmacists has to be investigated and defined in order to optimize treatment effectiveness and increase patient safety
- Research in medication adherence will help rethink our outpatient healthcare system





31

Ecole de Pharmacie

Thank you!

Prof. Chantal Csajka

Dr Ana Dorothea Wagner

Evelina Cardoso

Kim Ellefsen-Lavoie

Saskia Wherli

Dr Nicolas Widmer

All the pharmacists and technicians, Pharmacy, PMU

All the patients participating in the OpTAT study

Prof. Olivier Bugnon

marie.schneider@unige.ch







